Trials / Conditions / Lung Cancer, Small Cell

Lung Cancer, Small Cell

23 registered clinical trials studyying Lung Cancer, Small Cell — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Engagement of Veterans With Lung Cancer NCT07219251	Palo Alto Veterans Institute for Research	N/A
Not Yet Recruiting	Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy NCT06914050	Tianjin Medical University Cancer Institute and Hospital	Phase 2
Not Yet Recruiting	The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detecti NCT06739421	China-Japan Friendship Hospital	N/A
Recruiting	Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination The NCT06698965	Shanghai Chest Hospital	Phase 2
Unknown	Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan NCT06293833	University Hospital, Antwerp	N/A
Recruiting	A Study on the Efficacy of Atezolizumab Combined with Chemotherapy NCT06780826	Shanghai Pulmonary Hospital, Shanghai, China	—
Unknown	Pulmonary Rehabılıtatıon Wıth Non-Small Lung Cancer NCT05320458	Hasan Kalyoncu University	N/A
Unknown	A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Thera NCT05228496	Zhejiang Cancer Hospital	Phase 2
Completed	Trial of NanoPac Intratumoral Injection in Lung Cancer NCT04314895	NanOlogy, LLC	Phase 2
Active Not Recruiting	CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929	Carisma Therapeutics Inc	Phase 1
Active Not Recruiting	NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer NCT04986670	Tufts University	N/A
Unknown	Feasibility of Wearable Activity Trackers for Detection of TOXicity in People Receiving Systemic Anticancer Tr NCT04440800	Royal Marsden NHS Foundation Trust	—
Terminated	Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA NCT03499678	HKGepitherapeutics	—
Terminated	A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects W NCT01313663	GlaxoSmithKline	Phase 2
Completed	Regulatory Hycamtin(Oral) PMS NCT01037023	GlaxoSmithKline	—
Completed	SCOT Registry: Small Cell Lung Cancer Treatment and Outcome NCT00997061	GlaxoSmithKline	—
Completed	Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer NCT00698516	GlaxoSmithKline	Phase 2
Completed	First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Parapl NCT00316186	GlaxoSmithKline	Phase 2
Completed	A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced So NCT00259935	GlaxoSmithKline	Phase 1
Completed	The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cance NCT00043862	GlaxoSmithKline	Phase 2
Completed	Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer NCT00320359	GlaxoSmithKline	Phase 3
Completed	A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors NCT00046111	GlaxoSmithKline	Phase 1
Completed	Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small C NCT00276276	GlaxoSmithKline	Phase 3